By remaining involved beyond the transaction, Sunrise Enterprises seeks to provide customers with greater confidence in both the materials supplied and the support accompanying them
Mitesh Shah, Proprietor, Himanshu Shah, Procurement Head
The pharmaceutical industry's ability to deliver safe, effective medicines depends considerably on the quality and reliability of the ingredients used in their manufacture. Active Pharmaceutical Ingredients (APIs), in particular, form the foundation of pharmaceutical formulations, making dependable sourcing, regulatory compliance, and supply-chain transparency critical to manufacturers. As India's pharmaceutical industry strengthens its global presence, the need for trusted sourcing partners capable of connecting domestic manufacturers with established international suppliers continues to grow.
Recognising this need, Sunrise Enterprises has built its business around a straightforward yet demanding proposition: making quality pharmaceutical ingredients accessible through dependable global sourcing partnerships. Established in 2009, the company connects Indian pharmaceutical manufacturers with reputed international API producers, combining product quality, regulatory diligence, and relationship-driven service. With a network of over 100 partners and a customer base exceeding 1,200, Sunrise Enterprises has developed a presence across human and veterinary pharmaceutical markets, positioning itself as a sourcing partner that values long-term credibility over short-term commercial gains.
A Business Founded on Trust
When Sunrise Enterprises entered the pharmaceutical sourcing market in 2009, India's growing formulation industry presented a significant opportunity. The expanding demand for quality APIs created a need for reliable intermediaries who could connect domestic pharmaceutical companies with credible international manufacturers. The founders recognised that fulfilling this requirement would involve more than identifying suppliers and negotiating prices. It would require establishing confidence across a supply chain where product quality and consistency directly influence the end product.
“This understanding shaped the company's early business decisions. Sunrise Enterprises adopted a sourcing philosophy centred on working exclusively with trusted and certified manufacturers, refusing to compromise on quality for immediate commercial benefits. As a relatively new entrant competing in an established market, the company recognised that customer confidence would be its most valuable asset,” speaks Mitesh Shah, Proprietor.
Consequently, it focused on honouring commitments, understanding customer requirements, and maintaining consistency in service. These principles helped the company establish enduring relationships with customers and manufacturing partners, allowing its reputation to develop through dependable performance.
Partnerships That Strengthen Market Presence
In pharmaceutical sourcing, a strong supplier network is central to maintaining product availability and meeting evolving customer requirements. Sunrise Enterprises has steadily expanded its international relationships, building a network of more than 100 partners while serving over 1,200 clients.
Its trusted global manufacturing and supply network includes established companies such as Sinobright Pharmaceuticals Co., Synchem International Co., Zhejiang NHU Co., Hubei Hvsen Biotechnology, Zhejiang Goubang Pharmaceutical Co., Ningxia Taurui Pharmaceutical Co., and CSPC Group. These associations strengthen the company's access to international pharmaceutical manufacturing capabilities while reflecting its emphasis on quality, consistency, and long-term collaboration.
A particularly significant milestone came in 2014, when Zhejiang NHU appointed Sunrise Enterprises as its exclusive representative for Vitamin E in India. The association represented an important recognition of the company's market credibility and its ability to represent an established international manufacturer in a competitive domestic market.
More recently, the company secured exclusive representation for various veterinary APIs from Hubei Hvsen Biotechnology, strengthening its position in the veterinary pharmaceutical segment and expanding its product reach.
However, the company's approach to partnerships extends beyond representation agreements. The API market frequently experiences price fluctuations, changes in availability, and shifting supply conditions. There have been instances when market prices increased sharply after orders were confirmed, requiring Sunrise Enterprises to absorb financial losses to honour its commitments.
This willingness to protect customer interests, even when it affects immediate profitability, reflects the business philosophy that has shaped its growth. For Sunrise Enterprises, partnerships are built through consistent actions rather than commercial promises.
Quality Beyond the Product
The pharmaceutical supply chain operates within stringent quality and regulatory expectations. For API sourcing companies, maintaining product integrity involves evaluating manufacturers, verifying documentation, ensuring traceability, and coordinating appropriate storage and transportation.
“Sunrise Enterprises follows a selective sourcing approach, working with manufacturers that possess the necessary regulatory approvals, Good Manufacturing Practice (GMP) certifications, and established quality systems. This enables the company to align its sourcing practices with the compliance expectations of pharmaceutical customers,”shares Mitesh Shah.
Documentation is another important part of its operating process. Each shipment is accompanied by essential records, including Certificates of Analysis (COAs), Material Safety Data Sheets (MSDS), and other relevant certificates. These documents provide customers with the information required to assess product specifications, safety considerations, and traceability.
The company also ensures that APIs are supplied in their original manufacturer-sealed packaging, helping preserve authenticity and product integrity. Depending on product requirements, appropriate warehousing arrangements, including temperature-controlled facilities, are maintained.
Importantly, its involvement does not end with delivery. If customers encounter quality-related or technical concerns, Sunrise Enterprises coordinates with manufacturers to investigate and resolve issues. Where products are damaged during transit or storage, it takes corrective measures, including replacement wherever necessary.
By remaining involved beyond the transaction, Sunrise Enterprises seeks to provide customers with greater confidence in both the materials supplied and the support accompanying them.
Expanding Across Human and Veterinary Healthcare
While human pharmaceutical APIs formed the foundation of Sunrise Enterprises, the company has progressively expanded its presence in veterinary pharmaceuticals. Both segments have distinct market requirements but share an essential dependence on consistent product quality, regulatory compliance, and dependable supplier relationships.
Its association with Hubei Hvsen Biotechnology has been instrumental in strengthening the veterinary portfolio. Through this partnership, Sunrise Enterprises has developed a presence in several veterinary API categories and serves prominent names in the industry. The company considers this development a reflection of the confidence customers place in its sourcing capabilities and service consistency. By remaining involved beyond the transaction, Sunrise Enterprises seeks to provide customers with greater confidence in both the materials supplied and the support accompanying them
Supported by its established global manufacturing relationships, Sunrise Enterprises is positioned to explore additional product opportunities across both segments while maintaining the sourcing standards that have defined its business.
Operating in an increasingly competitive API distribution environment, Sunrise Enterprises believes that customers will become more discerning about the origins, quality, and documentation of their raw materials. Pharmaceutical manufacturers are placing greater emphasis on sourcing from certified suppliers capable of maintaining consistent standards and providing complete documentation.
“For Sunrise Enterprises, these developments reinforce the relevance of the principles on which the company was established. Its experience in managing supply fluctuations, coordinating with international manufacturers, and supporting customers through challenging market conditions provides a foundation for navigating an evolving industry,” says Mitesh Shah.
Strengthening the Next Phase of Growth
Sunrise Enterprises is approaching its next phase of growth by building on its established supplier relationships while exploring new international partnerships. A key priority is introducing additional molecules into the Indian market through its existing manufacturing partners, alongside developing associations with other reputed global suppliers.
An encouraging development has been the increasing interest shown by established international manufacturers in approaching the company to explore potential collaborations. Sunrise Enterprises views this as an indication of the credibility it has developed through years of consistent performance and its ability to meet the expectations of both customers and suppliers.
“The company also intends to expand its product portfolio across human and veterinary APIs, strengthening its ability to serve a broader range of pharmaceutical manufacturers. Our established relationships with international producers, particularly in China, are expected to support this expansion and create opportunities to introduce new products to the domestic market,” shares Mitesh Shah.
With an international network that includes established pharmaceutical manufacturers and supply partners, the company aims to translate these relationships into broader product availability, stronger sourcing capabilities, and sustained customer confidence.
Rather than pursuing expansion at the expense of operational consistency, Sunrise Enterprises remains focused on strengthening its existing business model. Its priorities continue to centre on dependable sourcing, product integrity, regulatory compliance, and responsive customer support.
After more than a decade and a half in pharmaceutical sourcing, Sunrise Enterprises recognises that its strongest differentiator lies in the trust it has built across its network. As pharmaceutical manufacturers increasingly seek reliable global sourcing partners, the company aims to deepen these relationships, broaden its portfolio, and reinforce its position in the industry. Its growth strategy remains tied to the principle that has guided the business since 2009: delivering on commitments and making reliability the foundation of every partnership.